亡灵机器人学：死去的身体，活着的机器

In the summer of 2022, a postdoc at Rice University pushed a needle into a dead tarantula, hooked it up to an air pump, and turned the valve. The spider's legs opened. As the pressure dropped, the legs closed again — gripping a circuit board in under a second. The spider had been dead for weeks.

The mechanics are simple. Spider legs don't move by muscle the way mammal limbs do; they run on internal hydraulic pressure. When the spider is alive, hemolymph pressure extends the legs. When it dies, the pressure drops, and the legs curl inward — which is why dead spiders are always found curled up. Faye Yap, working in Daniel Preston's lab, replaced the lost pressure with external air. The motion system was still intact. What death had removed was the power source, not the machinery.

The paper appeared in Advanced Science in July 2022 under the title "Necrobotics: Biotic Materials as Ready-to-Use Actuators." It named a new category. The following year, the work won an Ig Nobel Prize — the award given for research that "first makes you laugh, then makes you think." Three years on, the thinking is well underway.

Three Technical Pathways: Hydraulics, Olfaction, Microstructure

Since the original paper, necrobotics has split into three independent technical branches, each pointing at a different industry.

The shared logic is straightforward. Hundreds of millions of years of evolution have done the engineering — producing microstructures that human manufacturing cannot replicate at any reasonable cost. Death leaves those structures behind. The field's premise is not reanimation. It is borrowing what evolution already built.

From $125M to $2.14B

The bio-hybrid robotics market — covering both necrobotics and live tissue–based hybrids — is forecast to reach roughly $125 million in 2024 and grow to $2.14 billion by 2032, a compound annual growth rate of 35.4%. Medical applications account for 34.6% of the projected market. Asia-Pacific is the fastest-growing region (36.46% CAGR); North America holds over 40% of current revenue. The adjacent soft-robotics market sits at $1.89 billion in 2024 and is expected to reach $8.8 billion by 2030.

Public funding has tracked the trajectory. Between 2020 and 2024, the U.S. National Science Foundation and National Institutes of Health committed roughly $60 million to related research. In China, Shanghai Jiao Tong University has produced results in bio-hybrid flapping-wing robots, combining feather vibration structures with flexible piezoelectric materials. Shanghai municipal planning has formally listed bio-hybrid robotics in its industrial roadmap. No listed company is in the space yet. The distance between lab and commerce, however, is closing.

Commercialisation is most likely to materialise along three paths. The medical path is closest: FDA approval for biodegradable medical devices is well-established precedent, and the 20-micron precision of mosquito stylets makes them direct candidates for tissue-engineering scaffolds. The sensing path is second: moth antennae outperform existing electronic noses at trace detection, with disaster search-and-rescue and industrial leak monitoring as natural paying markets. The third path — crustacean exoskeletons recovered from shrimp and crab processing — converts waste streams into lightweight structural components, aligning neatly with circular-economy policy.

The raw material is, in effect, free. That is the unusual cost structure underwriting the field: material cost approaches zero. Value sits in integration, not extraction.

Where to Draw the Ethical Red Line

Current research concentrates on insects, spiders, and crustaceans. None of the three categories falls under animal-welfare protection in most jurisdictions. Crustacean exoskeletons in particular are already classified as food-processing by-product. The ethical bar is low — and that is part of what allows the field to move fast.

The technology does not stop at insects. A parallel research line uses live muscle tissue to drive miniature actuators; laboratories have produced motion by tetanic stimulation of ring-shaped muscle. The day that line moves out of the lab is the day necrobotics stops being about reused waste and starts being about deliberately raising or killing organisms for biological material. That is where the ethical ground gets uncertain.

No published research has yet extended necrobotics to mammalian parts. There is no principled technical barrier to doing so. A PNAS ethics paper has recommended that the academic community adopt institutional ethics statements — that every relevant paper include a cost-benefit analysis justifying the use of biological material. Once commercial pressure enters, the binding force of academic self-regulation will be tested.

The regulatory picture is, for now, empty. The European Union has no dedicated rules. Neither does the United States. Neither does China. The field has roughly three to five years of open space — technology iterating quickly, commercialisation moving in cautiously, and the rule-makers absent. Historically, that is the window in which an industry's governance tone is set.

Closing

The numbers make the commercial case difficult to dismiss. 20-micron print precision, 1:226 lift-to-weight ratio, gas detection at five metres — each sits at or near the best available in its engineering domain, with material costs close to zero. Necrobotics is not staying in the curiosity-of-the-month category.

Over the next five to ten years, commercial deployment is most likely in this order: medical microsurgery (mosquito stylet → tissue-engineering scaffolds), environmental sensing (moth antennae → industrial safety), then circular-economy components (crustacean shells → lightweight micro-robot parts). The three share one premise — the raw material is free; the value lies in integration.

The real uncertainty is not technological. It is regulatory. Whoever sets the ethical framework first sets the rules for a $2.1-billion market. The science is in front. The governance is still behind.